Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients

Autor: Glenn F. Van Wigcheren, Nienke De Haas, Tom A. Mulder, Sophie K. Horrevorts, Martine Bloemendal, Simone Hins-Debree, Yumeng Mao, Rolf Kiessling, Carla M.L. van Herpen, Georgina Flórez-Grau, Stanleyson V. Hato, I. Jolanda M. De Vries

Publikováno v: OncoImmunology, Vol 10, Iss 1 (2021)

Cancer immunotherapies have induced long-lasting responses in cancer patients including those with melanoma and head and neck squamous cell carcinoma (HNSCC). However, the majority of treated patients does not achieve clinical benefit from immunother

Externí odkaz: https://doaj.org/article/adc6216a88f3457ca14af7d610f19bd8

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

Autor: Lieke L. van der Woude, W. Joost Lesterhuis, Winald R. Gerritsen, Martine Bloemendal, Cornelis J. A. Punt, Michelle M. van Rossum, Marieke E. B. Welzen, Winette T. A. van der Graaf, Stanleyson V. Hato, Erik H.J.G. Aarntzen, Nienke de Haas, Mark A.J. Gorris, Kalijn F. Bol, Steve Boudewijns, I. Jolanda M. de Vries, Carl G. Figdor, Rutger H. T. Koornstra, Gerty Schreibelt, Harm Westdorp, Alexandra J. Croockewit, Anna L. de Goede

Publikováno v: Cancer Immunology, Immunotherapy
Cancer immunology, immunotherapy, 69(3), 477-488. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 69, 477-488
Cancer Immunology Immunotherapy, 69, 3, pp. 477-488

BackgroundAutologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccinati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcbb86b24d2d39a676b66fa918c38121
https://doi.org/10.1007/s00262-019-02466-x

STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics

Autor: Coco de Koning, Nienke de Haas, I. Jolanda M. de Vries, Georgina Flórez-Grau, Stefania Di Blasio, Stanleyson V. Hato

Publikováno v: Journal of Immunology Research
Journal of Immunology Research, 2019
Journal of Immunology Research, Vol 2019 (2019)

The STAT signaling pathway is important in dendritic cell (DC) development and function. Tumor cells can induce STAT signaling, thereby inhibiting DC maturation and immunostimulatory functions, leading to hampered efficacy of DC-based immunotherapies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1224f3c9637fbbe0c169706807ef191e
https://pubmed.ncbi.nlm.nih.gov/31309123

Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients

Autor: Elles Simonetti, Huberdina M. L. M. Brouwers, Gerty Schreibelt, Marc J. Eleveld, Florian Wimmers, Winald R. Gerritsen, Nienke de Haas, I. Jolanda M. de Vries, Anja Scholzen, Irma Joosten, Marien I. de Jonge, Dimitri A. Diavatopoulos, Marjo Beldhuis-Valkis, Joannes F M Jacobs

Publikováno v: Scientific Reports, 7
Scientific Reports

Contains fulltext : 170195.pdf (Publisher’s version ) (Open Access) Keyhole limpet hemocyanin (KLH) is used as an immunogenic neo-antigen for various clinical applications and during vaccine development. For advanced monitoring of KLH-based interve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d040be68320c9491ab7c4e053ffd2ea
https://hdl.handle.net/2066/170195

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition

Autor: Harm Westdorp, Nienke de Haas, Winald R. Gerritsen, Nielka P. van Erp, I. Jolanda M. de Vries, Stanleyson V. Hato, Rutger H. T. Koornstra, Vincent van Deutekom, Stefania Di Blasio, Carl G. Figdor, Jurjen Tel, Steve Boudewijns

Publikováno v: Journal of Translational Medicine, 14, pp. 88
Journal of Translational Medicine
Journal of Translational Medicine, 14, 88

Background Melanoma is the most lethal type of skin cancer and its incidence is progressively increasing. The introductions of immunotherapy and targeted therapies have tremendously improved the treatment of melanoma. Selective inhibition of BRAF by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eef0537c6b7ded9276e540ae7e519b2a
https://hdl.handle.net/2066/171226